Nicklaus Children’s brings bedside PDA closure to the NICU crib for fragile newborns

Nicklaus Children’s Health System has announced that the Nicklaus Children’s Heart Institute is introducing bedside transcatheter patent ductus arteriosus (PDA) closures for medically fragile newborns, a first-of-its-kind offering in Florida that could transform the way hospitals manage congenital heart conditions in neonatal intensive care units (NICUs). The announcement positions the institute as a leader in pediatric cardiac innovation, with the capability to deliver advanced catheter-based procedures directly at the infant’s bedside rather than in a catheterization laboratory.

Why does bedside transcatheter PDA closure represent a breakthrough for neonatal care in South Florida?

For decades, the standard practice for closing a PDA — a small fetal blood vessel that sometimes fails to seal naturally after birth — required transferring infants from the NICU to a catheterization laboratory or operating room. This step carried significant risks, particularly for premature babies whose fragile lungs and low body weight made them highly vulnerable to complications during transport.

The new bedside approach means the catheterization team comes directly to the NICU, performing the minimally invasive procedure while the baby remains inside their isolette or crib. By removing the need for transport, clinicians can lower the risk of destabilization and ensure continuity of care in a controlled environment. Families, in turn, are spared the anxiety of seeing their newborns wheeled away for high-stakes procedures.

Industry experts have noted that neonatal cardiac care has steadily moved toward less invasive, more localized treatments. The Nicklaus Children’s Heart Institute’s program builds on this trend, integrating advanced imaging and device technologies with the logistical flexibility required in neonatal environments.

How does PDA impact premature infants and why is timely closure so critical?

Patent ductus arteriosus occurs when a vascular connection that normally closes after birth remains open, causing excess blood to flow into the lungs. For preterm infants, this condition can create a cascade of complications, including difficulty breathing, delayed growth, poor feeding, and an increased risk of chronic lung disease.

Traditionally, doctors attempt to manage PDA with medication or through careful observation, since not all PDAs require closure. However, when these options fail, interventional procedures are needed to stabilize the infant’s condition. Bedside catheter-based closure uses a tiny device delivered through a vein to seal the PDA internally, avoiding the trauma of open-heart surgery.

The technique was pioneered by Dr. Shyam Sathanandam, who was recently appointed chief of cardiovascular medicine and co-director of the Nicklaus Children’s Heart Institute. Under his leadership, the hospital has adopted and advanced this procedure as part of its broader commitment to innovation in pediatric cardiology.

What role does leadership and innovation play in expanding pediatric cardiac care?

Dr. Sathanandam is widely recognized for developing minimally invasive methods to treat congenital heart defects in newborns. His appointment marks a strategic step for Nicklaus Children’s, which aims to cement its position as a leading pediatric cardiac care provider in the United States.

The hospital has announced that it expects to become the first in the nation to roll out a traveling PDA closure program. This would enable its specialist teams to visit other hospitals across South Florida, expanding access to families whose infants may not be stable enough for transfer. Such outreach aligns with broader healthcare trends, where specialized expertise is being decentralized and made mobile to reduce disparities in access to cutting-edge therapies.

In professional circles, analysts of the healthcare sector have suggested that hospitals with highly specialized programs like this often see increased philanthropic support, research partnerships, and long-term institutional prestige. While Nicklaus Children’s is not a publicly traded entity, its reputation-building efforts have parallels to brand equity development in corporate markets.

How does this fit into the historical trajectory of pediatric cardiac innovations?

Pediatric cardiology has evolved dramatically over the past 50 years. In the 1970s and 1980s, many infants with heart defects required full open-heart surgery, with survival dependent on long intensive care stays. By the 1990s and 2000s, interventional cardiology techniques began to replace surgical procedures, reducing mortality and shortening hospital stays.

In the last decade, advances in device miniaturization have allowed for catheter-based treatments to be performed even in extremely small preterm infants weighing less than 1 kilogram. The bedside transcatheter PDA closure now represents the next leap forward — not just a technical improvement, but a reimagining of care delivery by embedding advanced interventions directly into the NICU setting.

This mirrors larger healthcare trends, where precision medicine, point-of-care technologies, and minimally invasive therapies are converging to reshape treatment models. Analysts note that institutions able to integrate these innovations effectively often become referral hubs for complex cases, reinforcing their leadership in highly specialized fields.

What are the patient and family benefits of bringing catheterization directly to the NICU?

From the perspective of families, the innovation offers both practical and emotional relief. Parents no longer need to face the distress of watching their fragile newborns transported for procedures, and the risks associated with ventilator disconnections, infection exposure, and physiological instability are greatly reduced.

Clinical teams highlight additional benefits: no chest incision is required, recovery times can be faster, and the collaborative care model — with neonatologists, cardiologists, anesthesiologists, and nurses all present at the bedside — ensures that infants receive continuous multidisciplinary support.

The institute also emphasizes shared decision-making, noting that families are engaged at every stage. Each infant undergoes a tailored evaluation to determine whether observation, medication, or closure represents the safest and most effective course of action.

This emphasis on collaboration and individualized care aligns with the broader patient-centered care movement in American healthcare, which has become a key quality metric for hospitals and health systems nationwide.

How does this program strengthen Nicklaus Children’s positioning in pediatric cardiology?

Nicklaus Children’s Heart Institute already treats thousands of patients annually with congenital and acquired heart conditions. Its Pediatric and Congenital Catheterization Program is internationally recognized, often cited among the world’s leaders in complex interventional techniques. By introducing bedside PDA closures, the institute reinforces its status as a first mover in pediatric innovation.

The expansion not only enhances its clinical offering but also positions the institute as a model for replication nationwide. Industry observers anticipate that other children’s hospitals will soon follow with similar programs, potentially accelerating a shift in standard-of-care protocols for fragile neonates.

This reputational strength can have downstream effects: stronger recruitment of physician talent, more collaborative research opportunities, and broader appeal to philanthropic donors interested in supporting breakthroughs in pediatric health.

What is the broader outlook for minimally invasive neonatal therapies in the U.S.?

The bedside PDA closure program speaks to a larger shift in neonatal and pediatric care. As technology enables more precise and less invasive interventions, hospitals are rethinking where and how procedures can be safely performed. Analysts expect similar bedside innovations to emerge in areas such as neonatal respiratory support, point-of-care imaging, and precision drug delivery.

By being among the first to integrate such approaches, Nicklaus Children’s is setting benchmarks for the industry. Its leadership also provides a signal to policymakers and healthcare funders about the importance of investing in neonatal innovation to reduce costs, improve outcomes, and enhance family experience.

Looking ahead, the institute’s traveling program may represent an entirely new model of regionalized specialty care. If successful, this could inspire other institutions to adopt mobile approaches to pediatric cardiology and beyond, ensuring advanced care reaches patients where they are rather than requiring risky transfers.